Mark E Schmidt

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Profiling of hepatic clearance pathways of Pittsburgh compound B and human liver cytochrome p450 phenotyping
    Anne Van Vlaslaer
    Experimental Medicine, Janssen Research and Development, Division of Janssen Pharmaceutica, NV Turnhoutseweg 30, B 2340, Beerse, Belgium
    EJNMMI Res 3:10. 2013
  2. ncbi A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia
    Mark E Schmidt
    Janssen Research and Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium
    Eur Neuropsychopharmacol 22:721-33. 2012
  3. ncbi Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects
    Mark E Schmidt
    Johnson and Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340, Beerse, Belgium
    Psychopharmacology (Berl) 208:109-19. 2010
  4. ncbi The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory Board
    Mark E Schmidt
    Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium
    Alzheimers Dement 6:286-90. 2010
  5. ncbi D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection
    Mark E Schmidt
    Experimental Medicine, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium
    Psychopharmacology (Berl) 224:549-57. 2012

Collaborators

Detail Information

Publications5

  1. ncbi Profiling of hepatic clearance pathways of Pittsburgh compound B and human liver cytochrome p450 phenotyping
    Anne Van Vlaslaer
    Experimental Medicine, Janssen Research and Development, Division of Janssen Pharmaceutica, NV Turnhoutseweg 30, B 2340, Beerse, Belgium
    EJNMMI Res 3:10. 2013
    ..Subjects enrolled in AD trials may start or stop medications that inhibit or induce xenobiotic metabolizing enzymes such as the cytochrome P450 (CYP) isozymes...
  2. ncbi A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia
    Mark E Schmidt
    Janssen Research and Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium
    Eur Neuropsychopharmacol 22:721-33. 2012
    ..All JNJ-37822681 dose groups showed lesser weight gain compared with olanzapine. The efficacy and tolerability profile of the JNJ-37822681 10 mg bid was consistent with the study hypothesis...
  3. ncbi Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects
    Mark E Schmidt
    Johnson and Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340, Beerse, Belgium
    Psychopharmacology (Berl) 208:109-19. 2010
    ....
  4. ncbi The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory Board
    Mark E Schmidt
    Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium
    Alzheimers Dement 6:286-90. 2010
    ..Although positioned as an advisory body, ISAB also actively contributes to the ADNI mission of identifying biomarkers of disease progression...
  5. ncbi D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection
    Mark E Schmidt
    Experimental Medicine, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium
    Psychopharmacology (Berl) 224:549-57. 2012
    ..Receptor occupancy at steady state was explored to test the validity of the single-dose estimates during chronic treatment...